Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.43 |
| ▸ | PDE4A | P27815 | 6/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905188 | 0.84 | PDE5A (0.50) | PDE5AALDH1A1CYP3A4MAPTALOX15 | |
| SCHEMBL31377991 | 0.83 | ALDH1A1 (0.58) | ALDH1A1CYP3A4MAPTALOX15KDM4E | |
| SCHEMBL1766175 | 0.83 | ALDH1A1 (0.58) | ALDH1A1CYP3A4MAPTALOX15KDM4E | |
| SCHEMBL2906067 | 0.83 | PDE5A (0.49) | PDE5AALDH1A1CYP3A4MAPTALOX15 | |
| SCHEMBL28892853 | 0.82 | PDE5A (0.43) | PDE5APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL30002505 | 0.82 | PDE5A (0.43) | PDE5APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL8084461 | 0.82 | PPOX (0.46) | PDE5AALDH1A1CYP3A4MAPTALOX15 | |
| SCHEMBL7355696 | 0.81 | ALDH1A1 (0.71) | PDE5AALDH1A1CYP3A4MAPTALOX15 | |
| SCHEMBL22065381 | 0.80 | PDE5A (0.52) | PDE5ACYP3A4MAPTKDM4EPDE4D | |
| SCHEMBL20631457 | 0.80 | PDE5A (0.52) | PDE5ACYP3A4KDM4EPDE4DPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692109-B1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARM CORP (US) | 2010-08-18 | — | — | EP | disclosed |
| CN-1922144-A | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | MEMORY PHARM CORP (US) | 2007-02-28 | — | — | CN | disclosed |
| EP-1692109-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | Memory Pharmaceuticals Corporation (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | disclosed |
| WO-2005061458-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | PDE4A, PDE4B, PDE3B | PDE5A 7/4885ALDH1A1 300/4885CYP3A4 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.